Michael Hodges, MD.

Michael is a highly experienced and successful pharmaceutical industry veteran. He has worked on eight drug development programs in big PHARMA as the team leader/team member that has led to global regulatory approvals. Within biotech, he has been part of teams that have raised Series B and C rounds of financing (~$150MM), one F-1 submission for IPO, one reverse merger, and two successful M&As. He has deep disease-specific and RNA therapeutics technical expertise. He is currently supporting a number of Biotechnology companies in the role of drug development consultant, scientific advisor, and/or board director. He is a member of the science advisory boards of Arcturus Therapeutics, Exicure Therapeutics, and eFFECTOR Therapeutics and a scientific advisor for Adjuvant Capital.
Michael was previously the CMO of Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Before Amplyx he was the CMO for Santaris A/S, developing drug treatments for chronic viral diseases, cancer, metabolic/lipid, and eye diseases. The company was acquired by Hoffman-La Roche, AG.
Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs were approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin).
Michael was a Non-Executive Director of F2G Ltd., an infectious disease biotechnology company from 2010-2014. He earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.

Clement Lewin, Ph.D., MBA.

Clement Lewin is a Principal at CSL Vaccine Consulting with expertise in medical affairs, policy, and strategy. Until the end of 2020, he headed the BARDA Office and NV Stakeholder Engagement for Sanofi Pasteur where he played an instrumental role in securing and managing over $2 billion in BARDA funding for pandemic influenza and COVID-19 vaccines development as well as serving as one of the external spokespeople for the COVID-19 program.

Clem has 25 years of experience in vaccines in roles of increasing responsibility. He started at Merck and held several domestic and international positions. At Chiron Vaccines, he served as Vice President Strategic Planning & Business Intelligence and then Vice President Government Affairs & Immunization Policy for the US. He then joined Acambis overseeing Government Affairs, the Strategic Planning process, and Marketing playing a key role in licensing ACAM2000, a cell culture-based smallpox vaccine, and securing a ten-year $450 million contract with the United States Government to supply the vaccine. Clem headed Medical Affairs & Immunization Policy for North America where he was responsible for Medical Affairs activities; the CDC and National Vaccine Program Office helping launch several vaccines and manage the response to the 2009 pandemic. In addition to his experience in vaccines, Clem was at Bayer Pharmaceuticals as Director of Global Scientific Affairs for their anti-infective franchise.

Clem obtained his BSc and Ph.D. from the University of London. After five years as a Research Fellow at the Universities of London and Edinburgh. He published over 50 papers in peer-reviewed journals on mechanisms of action and resistance to antibacterials leaving research to obtain an MBA with distinction from Cornell University and joining the life sciences practice of Pittiglio Rabin Todd & McGrath, specializing in product development issues.

Clem was the Biotechnology Innovation Organization liaison to the Advisory Committee on Immunization Practices from 2004 to 2014. He served on the National Vaccine Advisory Committee from 2009-2012. He was on the advisory board of Bio Ventures for Global Health and a board member of the Alliance for Biosecurity. He currently serves on the Board of Trustees of Gaylord Hospital, a long-term acute care facility in Connecticut.

Bruce Forrest, MD.

Dr. Bruce Forrest serves as the President of Hudson Innovations, LLC, and as Co-Head of Life Sciences Investment Banking, Young America Capital, LLC. Dr. Forrest received his MD at the University of Adelaide, Australia, in 1991. He possesses over 25 years of global leadership in pharmaceutical development with expertise in, but not limited to, vaccines and biopharmaceuticals development in both major and emerging markets. During his career in the pharmaceutical and medical device industry, Dr. Forrest was the clinical leader for several major vaccine programs, including a meningococcal C conjugate vaccine; a live, rotavirus vaccine; a pneumococcal conjugate vaccine; and a live attenuated influenza vaccine. As a Senior Vice President at Wyeth Pharmaceuticals, Bruce was responsible for all late-phase development activities in Wyeth Vaccines Research. He led both clinical and pharmaceutical science development, including Fermentation and Process Development, Analytical Development, Formulation Development, GMP testing, Development Project Management, GMP Clinical Supplies Manufacturing and Distribution, Outsourcing Management, and Development Finance.

In addition, Bruce Forrest has extensive experience and field knowledge of the pharmaceutical development environment in Asia, especially Japan, where he served as Board Member, Corporate Officer, and Executive Director (Head) of R&D for Wyeth K.K. He oversaw the local product approvals for etanercept and gemtuzumab ozogamicin, as well as product registration submissions for a pneumococcal conjugate vaccine, bazedoxifene, temsirolimus, venlafaxine, and tigecycline; and, was responsible for developing a successful strategy for the integration and coordination of development activities across the major markets in East Asia.

M. Javad Aman, Ph.D.

Dr. Aman is a molecular immunologist and corporate executive with over 30 years of experience in the field of immunology, microbiology, and vaccine and immunotherapeutics development for infectious diseases. Dr. Aman founded Integrated BioTherapetics and grew the business, not a clinical-stage company, and raised over $100M in non-dilutive funding. He graduated from the school of Pharmacy at the University of Frankfurt in 1990. Dr. Aman later went on to complete his Ph.D. in molecular immunology at Johannes Wolfgang University in Mainz, Germany and continued his research at NIH and the University of Virginia. He then built his independent research program at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) as a Principal Investigator on the development of vaccines for bacterial toxins such as staphylococcal and B. anthracis toxins as well as viral hemorrhagic fever viruses. Dr. Aman has published over 120 papers ranging from basic research in hematology, signal transduction, to vaccine and antibody discovery for infectious diseases in international scientific journals.